tofacitinib - Generic mfg.
Jakafi (ruxolitinib) - Incyte
Rinvoq (upadacitinib) - AbbVie
Olumiant (baricitinib) - Eli Lilly
Janus kinase inhibitors in the management of lichen planus: a systematic review. (PubMed, Ann Med) - Oct 8, 2026 - "There were 13 papers on tofacitinib, six on baricitinib, and two papers each on ruxolitinib and upadacitinib. Several case series and case reports have shown beneficial effects of JAK inhibitors to treat LP. Few patients had minor adverse events." 
Journal • Review • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation • Lichen Planus
http://www.ncbi.nlm.nih.gov/pubmed/42841678
 
Abeer G Almutairi; Asem Shadid; Atheer G Almutairi; Azzam Alkhalifah; Houriah Nukaly; Leena I Aloraini; Saleha Khan
 
Oct 8, 2026
 
Prev Next